ИММУНОТЕРАПИЯ В ОНКОЛОГИИ: ИНГИБИТОРЫ КОНТРОЛЬНЫХ ТОЧЕК // ФОНД "ХОЛАНГИОКАРЦИНОМА" // ЖУКОВА Н.В.

Webinar "IMMUNOTHERAPY IN ONCOLOGY: CHECKPOINT INHIBITORS" supported by the CHOLANGIOCARCINOMA Charitable Foundation NATALIA VLADIMIROVNA ZHUKOVA, oncologist, chemotherapist, head of the antitumor drug therapy department at the Beloostrov High-Tech Clinic, MMC, PhD Immunotherapy has become an integral part of antitumor drug treatment. "Checkpoints" in cells must be activated or inactivated so that the immune system can once again recognize malignant cells. A number of drugs, including pembrolizumab, durvalumab, atezolizumab, and nivolumab, are aimed at restoring immune system function. What is their mechanism of action, and how do they differ among the different drugs? - What are the differences in adverse events (autoimmune reactions)? What are the options for prescribing immunotherapy? These and other questions were discussed during the webinar. OUR RESOURCES: Website: https://oncoliver.com VK: https://vk.com/oncoliver Telegram: https://t.me/ONCOLIVER YouTube:    / @oncoliver   Rutube: https://rutube.ru/u/oncoliver/ Brochure on biliary tract cancer: https://oncoliver.com/broshuraporakug... Community of biliary tract cancer patients and their loved ones: https://oncoliver.com/communityofpati...